EGFR and non-small cell lung carcinoma: Osimertinib (HR, 0.54, 95% CI, 0.32–0.90) and osimertinib + CT (HR, 0.48, 95% CI, 0.26–0.88) exhibited correlation with significant improvements in the OS of advanced EGFR-mutated NSCLC cases relative to befotertinib.